Kerstipon

Rivastigmine, the active ingredient in Kerstipon, is a acetylcholinesterase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease dementia in adult patients. GNH USA supplies Kerstipon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kerstipon, an acetylcholinesterase inhibitor, is used in neurodegenerative conditions that affect cognition. - Mild to moderate Alzheimer’s disease: improves cognitive function and daily living activities. - Parkinson’s disease dementia: helps maintain attention, memory and executive function.

Kerstipon may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes, especially at treatment initiation. - Diarrhea: loose stools that may be transient. - Loss of appetite: reduced desire to eat. - Weight loss: gradual decrease in body weight. - Dizziness: feeling light‑headed or unsteady.

Serious or Rare Side Effects: - Severe vomiting: persistent and may lead to dehydration. - Gastrointestinal bleeding: blood in stool or vomiting. - Bradycardia: unusually slow heart rate. - Syncope: fainting episodes. - Severe skin reactions: rash, Stevens‑Johnson syndrome. - Elevated liver enzymes: signs of hepatic stress.

Before initiating Kerstipon, clinicians should consider several safety measures. - Assess renal function: adjust therapy in severe impairment. - Monitor gastrointestinal symptoms: report persistent nausea, vomiting or diarrhea. - Evaluate cardiac status: watch for bradycardia or syncope. - Avoid in patients with known hypersensitivity to rivastigmine or related compounds. - Store at room temperature: keep in the original container, protect from moisture and light.

Kerstipon can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Anticholinergic drugs: may counteract rivastigmine’s effect. - Beta‑blockers: can exacerbate bradycardia. - Other acetylcholinesterase inhibitors: risk of additive cholinergic toxicity.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase nausea. - Antihypertensives: potential for enhanced hypotensive response. - General anesthetics: may potentiate cholinergic effects during surgery.